Strata Oncology的封面图片
Strata Oncology

Strata Oncology

生物技术研究

Ann Arbor,MI 13,090 位关注者

关于我们

Strata Oncology is a high-growth, state-of-the art, precision oncology company, delivering a new standard of care that integrates molecular profiling, decision support and clinical trial participation into routine practice. We do this by partnering with major healthcare systems across the country, who systematically send their cancer patients’ biopsies to our high-throughput CLIA lab for genomic sequencing, with results provided to the oncologist within days, indicating the tumor profile, and matches to appropriate therapies and drug trials. This accelerates the move to personalized medicine – right medicines to the right patients at the right time. Our personnel are passionate about and committed to making a positive difference, now, in the lives of cancer patients and their families. Clinicians, pathologists, bioinformaticists, software engineers, lab technicians and more, coming together to give access to those without, uncovering insight that might be hidden, all while spreading urgency to all. Experience a career that connects a fast-paced team environment with a worthy pursuit – feel good about what you’ve accomplished at the end of every day!

网站
https://www.strataoncology.com
所属行业
生物技术研究
规模
51-200 人
总部
Ann Arbor,MI
类型
私人持股
领域
precision oncology、next-generation sequencing、oncology和clinical trials

地点

  • 主要

    8170 Jackson Rd.

    Suite A

    US,MI,Ann Arbor,48103

    获取路线

Strata Oncology员工

动态

  • 查看Strata Oncology的组织主页

    13,090 位关注者

    Exciting news for all involved in the development and clinical use of ADCs! ? Strata Oncology?is unveiling new data at ASCO on Strata’s ADC Treatment Response Scores (ADC-TRS), an advanced, pan-tumor biomarker that predicts response for multiple ADCs.?We invite you to visit our poster, "Evaluation of a Predictive Biomarker for Antibody Drug Conjugates (ADCs)", and speak to us about how our biomarker can support significant label expansion for on market ADCs and derisk ongoing or planned trials for investigational ADCs.? ? The study, conducted in collaboration between Kaiser Permanente Northern California (KPNC) and Strata Oncology, concluded: ? ??ADC-TRS status significantly associated with overall survival (OS) after ADC treatment initiation in both KPNC and non-KP cohorts. ??ADC-TRS significantly improved model fit for OS beyond target gene expression alone. ??More than 25% of all patients with advanced solid tumors are predicted to respond to one or more approved ADCs outside of current indications. ? We look forward to connecting with you to discuss how Strata’s ADC Treatment Response Scores can advance your development plans and unlock opportunities for more patients to benefit from ADCs. ? #ASCO2024 #PrecisionMedicine #CancerResearch #Oncology #ADCs #ADCDevelopment?

    • 该图片无替代文字

相似主页

查看职位

融资